Using the PEG framework with analyst consensus forward EPS growth of 25.0% plus 0.6% dividend yield, Bio-Techne Corporation has a fair value of $49.61 based on NTM EPS (FY2026) of $1.98. The current PEG ratio is 0.56.
PEG < 1 = bargain, 1–1.5 = fair, > 2 = expensive.
Growth above 25% is capped — hypergrowth may not be sustainable long-term.
| EPS Growth RateForward | 46.9% |
| Dividend Yield | +0.6% |
| Adjusted Growth (clamped 8–25%)Clamped | 25.0% |
| Fair P/E | 25.0x |
| NTM EPS (FY2026) | $1.98 |
| Fair Value | $49.61 |
| Period | EPS Est. | Growth | Analysts |
|---|---|---|---|
| FY2025 (actual) | $0.46 | — | — |
| FY2026E | $1.98 | +331.4% | 11 |
| FY2027E | $2.18 | +10.0% | 10 |
| FY2028E | $2.52 | +15.4% | 7 |
| FY2029E | $3.03 | +20.3% | 3 |
| FY2030E | $3.15 | +4.0% | 3 |
5Y Forward EPS CAGR: 46.9%
The PEG Fair Value uses the Price/Earnings-to-Growth framework. A stock is fairly valued when its P/E ratio equals its earnings growth rate (PEG = 1.0). This model adds dividend yield to the growth rate per the original PEGY formula.
Growth rate priority: analyst consensus forward EPS CAGR (when ≥ 3 analysts cover the stock), falling back to historical EPS CAGR. Using EPS rather than net income avoids distortion from share buybacks. The growth rate is clamped between 8% and 25% — below 8% would undervalue stable earners, while above 25% would overvalue unsustainable spikes.
| Year | Net Income | EPS | YoY |
|---|
| FY2021 | $140.4M | $0.87 | — |
| FY2022 | $272.1M | $1.66 | +90.8% |
| FY2023 | $285.3M | $1.76 | +6.0% |
| FY2024 | $168.1M | $1.05 | -40.3% |
| FY2025 | $73.4M | $0.46 | -56.2% |
4Y Historical EPS CAGR: -14.7%